In the global fight against HIV, a twice-yearly injection could represent a seismic shift in prevention efforts. Lenacapavir, Gilead Sciences’ (NASDAQ: GILD) innovative therapy for HIV pre-exposure prophylaxis (PrEP), is not only a breakthrough in clinical efficacy but also a model for advancing equitable healthcare access.

‍

Read the full article by Chase Feiger on forbes.com